Probenecid markedly reduces urinary excretion of ethinylestradiol and trimethoprim slightly reduces urinary excretion of clenbuterol

Abstract

This study investigated whether the illegal application of ethinylestradiol or clenbuterol in cattle as growth promotors may be concealed by co‐treatment with drugs that affect urinary excretion. Therefore, six male veal calves were fed with ethinylestradiol and six different male veal calves were fed with clenbuterol for 13 days. Both groups received the growth promotors twice daily (days —2 to 11) with milk replacer. The calves receiving ethinylestradiol were additionally fed with probenecid on days 7–11, and the calves receiving clenbuterol were additionally fed wtih trimethoprim (days 7–11). During days 1–11 of the experiment, 24‐h urine and blood samples (once daily) were collected and analysed for ethinylestradiol and clenbuterol by specific enzyme immunoassay. In four calves the average urinary excretion of ethinylestradiol during days 7–11 (co‐treatment with probenecid) was only about 25% of their average urinary excretion of ethinylestradiol on days 1–6. In the other two calves of this group, the excretion of ethinylestradiol was reduced to 4% on days 7–11 compared with days 1–6. In these two calves several urine samples provided concentrations of ethinylestradiol around the limit of detection. As a consequence, there may be a chance of concealing ethinylestradiol application by co‐treatment with probenecid. Co‐treatment with trimethoprim led only to a slight reduction of urinary excretion of clenbuterol. The detection of clenbuterol in urine samples from calves which were co‐treated with trimethoprim can thus not be prevented.

Keywords:

• ethinylestradiol
• probenecid
• clenbuterol
• trimethoprim
• urinary excretion
• urine samples
• pharmacologic manipulation
• drug‐drug‐interaction
• renal transport

Notes

Present address: F. Hoffmann‐La Roche Ltd, Vitamins Exploratory Research, CH‐4070 Basel, Switzerland.